
an ABL switch control inhibitor with IC50 of 0.8 and 2 nM for respectively. DCC-2036 strongly prevents both unphosphorylated and a type II inactive conformation, and retains efficacy against the majority mutants, including T315I. DCC-2036 suppresses BCR-ABL1(T315I)-expressing survival in mouse models of T315I mutant CML and B-lymphoblastic patient leukemia cells expressing T315I in vitro and in vivo, supporting